Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab
Status:
Active, not recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Liver is the most common site of metastases from colorectal cancer. Neoadjuvant chemotherapy
with targeted agents is usually recommended for borderline-resectable liver metastases that
are technically difficult to resect for conversion to resectable disease and control of
metastatic spread. However, the prognosis of these patients are still poor, and long term
disease-free survival over 3 years is rare and <20%. More effective measures to prevent
recurrence are needed before or after resection of colorectal liver metastases.